Over a 6-year period, Merck gained an addition $3 billion in revenue from price increases on melanoma drug Keytruda.
Archive
Takeda gained $2 billion over the last 6 years from price increases on Entyvio, a drug for ulcerative colitis and Crohn’s disease.
From 2011–2017, Novo Nordisk raised the net price on diabetes drug Victoza by 32%.
Since 2014, Pfizer has garnered $5.6 billion from price increases on rheumatoid arthritis drug Xeljanz.
Since 2012, AbbVie has gained $49 billion in revenue from price hikes on Humira, a drug for rheumatoid arthritis and other inflammatory diseases.
Since 2012, 76% of revenue growth from multiple sclerosis drug Gilenya came from higher prices totaling $8 billion.
J&J has gained $14 billion over 10 years from price increases on immunosuppressant drug Stelara.
The price of multiple sclerosis drug Aubagio increased 78% from 2013 to 2020.